Atomwise

Atomwise: AI Molecular Docking Platform

Atomwise is the pioneer of deep learning for molecular docking — using its AtomNet neural network to screen billions of small molecules against protein targets in silico, identifying drug candidates orders of magnitude faster than physical screening. Founded 2012, well before the current AI biotech wave.

Hundreds of pharma + biotech partnerships including Bayer, Eli Lilly, and many academic medical centers via the Artificial Intelligence Molecular Screen (AIMS) program — making Atomwise's technology one of the most-deployed AI drug discovery platforms in academic and industry workflows.

Key Features

• AtomNet — deep learning for molecular docking
• Screens billions of compounds against protein targets
• AIMS academic program — broad partnerships
• Pharma deals: Bayer, Eli Lilly, others
• Pioneer (founded 2012) of AI drug discovery

Ideal Use Case

Pharma + biotech teams running structure-based drug discovery programs who want AI screening at billion-molecule scale — particularly for difficult targets where physical screening is cost-prohibitive.

Why Use Atomwise

Many newer entrants in AI drug discovery, but Atomwise's 12+ year history and AIMS academic partnerships have produced more validated AI-discovered hits than virtually any peer. Deep moat in benchmark performance and partnerships.

FAQ

Q: How many compounds screened? A: Billions per target — orders of magnitude beyond physical screening.

Q: Public? A: Private.

Q: AIMS program? A: Academic partnership program providing AI screening to research institutions globally.

tl;dr

AI molecular docking pioneer. AtomNet screens billions of molecules. Bayer, Lilly, academic AIMS partners.

Related

Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. Atomwise is also tracked on Crunchbase.